Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer

Last updated: December 15, 2024
Sponsor: Yunnan Cancer Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer

Lung Cancer

Non-small Cell Lung Cancer

Treatment

Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer

Clinical Study ID

NCT06742021
KYLX2024-272
  • Ages 18-75
  • All Genders

Study Summary

This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Tumor size greater than 2 cm

  2. Age between 18 and 75 years

Exclusion

Exclusion Criteria:

  1. Presence of MRI contraindications (e.g., metal implants, pacemaker implantation,etc.)

  2. Allergy to gadolinium contrast agents

  3. Lesions difficult to delineate on images due to conditions such as atelectasis ordiffuse lesions

Study Design

Total Participants: 195
Treatment Group(s): 1
Primary Treatment: Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
Phase:
Study Start date:
November 11, 2024
Estimated Completion Date:
July 31, 2026

Connect with a study center

  • Yunnan Cancer Hospital

    Kunming, Yunnan
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.